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idovudine (RetrovirTM) is one of the best
known agents used in the treatment ofwomen
with human immunodeficiency virus type-1 (HIV-
1) infection. This generally well-tolerated agent
has become a mainstay for the prevention of
mother-to-child HIV-1 transmission and is often a
component of combination antiretroviral regimens
utilized for the treatment of both adult and pedi-
atric HIV-1 infected individuals.
STRUCTURE AND DERIVATION
Zidovudine (ZDV,AZT, 3’-azido-3’-deoxy-
thymidine) is a synthetic nucleoside analogue of a
naturally occurring nucleoside, thymidine, in which
the 3’-hydroxy (-OH) group is replaced by an azido
(-N3) group (Fig. 1).
MECHANISM OF ACTION
Zidovudine (ZDV,AZT) is one of a class of human
immunodeficiency virus type-1 (HIV-1) antiviral
agents known as dideoxynucleoside reverse tran-
scriptase inhibitors (NRTIs). ZDV inhibits HIV-1
reverse transcriptase, the enzyme needed to cata-
lyze the synthesis of proviral double-stranded
DNA from the RNA template (Fig. 2), and there-
fore interferes with a critical step in the HIV viral
life cycle. The antiviral activity of ZDV depends
on the intracellular conversion of the drug to a tri-
phosphate metabolite and requires intracetlular
host cell kinases for conversion to this active 5’-
triphosphate form. The active 5’-triphosphate has
an affinity for HIV reverse transcriptase and com-
petes with endogenous triphosphate nucleotides
for incorporation into the newly synthesized pro-
viral DNA. ZDV triphosphate lacks a free 3’-hy-
droxyl group. In order for nucleic acid replication to
occur, the 3’-hydroxyl of a naturally occurring
nucleoside is the acceptor for covalent attachment
of subsequent nucleosides 5’-monophosphate.
When ZDV triphosphate is incorporated, it acts as
a chain terminator preventing further elongation of
the viral DNA chain.
In addition to ZDV, the other NRTIs that are
approved by the Food and Drug Administration
(FDA) are didanosine (ddi), zalcitibine (ddC),
stavudine (d4T), and lamivudine (3TC). Although
the structure and mechanism of action of all the
nucleoside analogues are similar, they differ signifi-
cantly in their intracellular phosphorylation path-
ways and kinetics, which contribute to differences
in their in vitro antiretroviral activity and pattern of
toxicities. The NRTIs have a wider spectrum of
antivirat activity than the other available HIV-1 an-
tiviral agents. Other classes of antiviral agents that
have been approved by the FDA for the treatment
of HIV disease are non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), which include ne-
virapine and delaviridine, and the HIV protease
inhibitors which include ritonavir, saquinavir, indi-
navir, and nelfinavir. HIV protease inhibitors have
greater activity than either NRTIs or NNRTIs
against HIV-1; these compounds were specifically
designed based on the ,structure of the HIV prote-
ase enzyme and have a spectrum of activity limited
to HIV-1 and to a lesser extent HIV-2.
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Fig. I. Structure of zidovudine (ZDV,AZT, 3’-azido-3’-
deoxythymidine).
PHARMACOKINETICS
Zidovudine is rapidly absorbed by the gastrointes-
tinal tract following oral administration with peak
serum concentrations occurring within 0.4-1.4
hours. Absorption shows considerable interindivid-
ual variation and is influenced by the time and
content of the last meal. Once absorbed, prior to
systemic distribution, zidovudine undergoes sig-
nificant first-pass metabolism, giving an average
bioavailability of 63%. Zidovudine is approxi-
mately 25% protein bound, primarily to albumin.
Zidovudine distributes into cells by passive diffu-
sion and is relatively lipophilic; it can be detected
in fluids other than plasma, which contributes to its
large distribution volume. Zidovudine is primarily
metabolized by liver through hepatic 5’-gluc-
uronidation, forming a stable glucuronidated me-
tabolite (GZDV) that is excreted by the kidneys.
Approximately 14-20% of unchanged drug and 60-
70% of its major metabolite are excreted in the
urine following oral or intravenous administration.
Administration of the same standard dose of oral
zidovudine results in a variable plasma concentra-
tion among adults. The variability is a consequence
of between-patient differences in the absorption,
distribution, metabolism, and clearance of the
drug. Although the plasma pharmacokinetic char-
acteristics have been well studied, the therapeutic
range of ZDV and the importance of intracellular
pharmacokinetics are not completely understood.
Therefore, the optimal dosing strategy for ZDV has
not been determined. Recommended doses (see
Table 1) are based on clinical endpoints, and not
on pharmacodynamic considerations.
Pharmacokinetics in pregnancy have been stud-
ied.z-4 ZDV and GZDV have been detected in the
fetus, amniotic fluid, and breast milk. Transplacen-
tal transfer of ZDV is by passive diffusion,s there-
fore, maternal plasma concentrations will be a ma-
jor determinant of fetal concentrations.6,7 Preg-
nancy introduces additional sources of variability in
the plasma drug concentration, including changes
in volume of distribution (expanded plasma vol-
ume, increased adipose tissue and the addition of a
fetal compartment), changes in drug clearance (in-
crease in cardiac output and a concomitant increase
in renal blood flow), and increases in hepatic me-
tabolism. Preliminary reports of zidovudine dispo-
sition in obese pregnant women found that achiev-
able plasma concentrations were far lower than ex-
pected based on population pharmacokinetic
information.8 In addition, information from the
AIDS (acquired immunodeficiency syndrome)
Clinical Trial Group (ACTG) 076 study suggests
that maternal obesity may be a risk factor for the
failure of ZDV prophylaxis to prevent perinatal
HIV-1 transmission. (R. Sperling, personal commu-
nication)
CLINICAL APPLICATIONS
(DEMONSTRATED EFFICACY)
Treatment of Adult Patients
Zidovudine has been extensively studied in the
treatment of patients with HIV infection whose
CD4+ cell counts are -<500 cells/mm3. In initial
studies, ZDV reduced the risk of disease progres-
sion, opportunistic infections, and death in patients
with advanced HIV disease.9 Further experience
with the drug revealed that the clinical benefits of
ZDV monotherapy were not sustained over the
long term. Recent studies have shown that the use
ofZDV as part of a combination antiretroviral regi-
men results in suppression of viral replication and
greater clinical benefits, including survival out-
come, when compared with ZDV alone.1
Prevention of Mother-to-Child HIV-I
Transmission
In February 1994, the National Institutes of Health
(NIH)-sponsored ACTG 076 study was closed to
enrollment and unblinded when an interim analy-
sis demonstrated that a regimen that combined ma-
ternal and newborn ZDV could dramatically reduce
the risk of mother-to-infant HIV-1 transmission.1
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Fig. 2. Life cycle of HIV.
The availability of a regimen that could reduce the
transmission of a fatal pediatric disease led the
United States Public Health Service lz to develop
consensus guidelines for clinicians about the use of
ZDV during pregnancy. Since implementation of
these guidelines, additional information about the
efficacy of ZDV for the prevention of perinatal
transmission has become available.
In November 1996, an efficacy update from the
ACTG 076 study confirmed the interim findings.
The original report was a Kaplan-Meier estimate of
the transmission risk and was based on 363 mother-
infant pairs. The recent update included 402
mother-infant pairs, all ofwhom had completed the
18-month infant follow-up; the rate of HIV-1 trans-
mission was 7.6% with ZDV treatment and 22.6%
with placebo (P < .001). 1"
In March 1997, enrollment in another pediatric
ACTG study, Protocol 185, was stopped due to an
unexpectedly low transmission rate in both study
arms. lz The ACTG 185 was a randomized, con-
trolled clinical trial which compared HIVIG (an im-
munoglobulin preparation containing high levels of
antibodies to HIV) to IVIG (standard immunoglob-
ulin) to determine whether HIVIG could further
reduce the risk of mother-to child transmission if it
was added to the maternal-child ZDV regimen suc-
cessfully utilized in ACTG 076. The ACTG 185
study was designed for women with more advanced
immunosuppression than the 076 study. In ACTG
076, all women had CD4+ T-cell counts exceeding
200 cells/mm3, and only 5% had received any prior
ZDV; in contrast, in ACTG 185, 23% had baseline
CD4+ cell counts less than 200 cells/mm3, and 21%
of women had received prior ZDV. After analyzing
outcomes in 379 infants, the estimated overall rate
of mother-to-infant HIV transmission was 4.8%
with no difference between HIVIG and IVIG re-
cipients. 14 The utility of prophylactic ZDV in preg-
nant women with advanced immunosuppression
that was demonstrated in ACTG 185 is consistent
with other reports. s,16
In February 1998, enrollment in a trial con-
ducted by the Ministry of Public Health of Thai-
land (in collaboration with the Centers for-Disease
Control and Prevention [CDC]) was stopped when
an interim analysis demonstrated the success of a
short-course of maternal antepartum/intrapartum
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TABLE I. Zidovudine dosing considerations
Mode of Dosage
Medication action form Dosing
Major Drug Pregnancy
toxicities interactions considerations
Zidovudine
(AZT, ZDV,
Retrovir)
Nucleoside
reverse
transcriptase
inhibitor
(NRTI)
100 mg capsules
300 mg tablets
Syrup: 50
mg/ml IV: 10
mg/ml
Also available in
combination
with 3TC
(Combvir-AZT
300 mg/3TC
150 mg)
Adults:
100 mg orally 5
times per day
(dose studied
in perinatal
prevention
trials)
200 mg orally 3
times per day
300 mg orally
twice a day
Intravenous in
labor: 2 mg/kg
loading dose,
followed by
continuous
infusion of
mg/kg/hr
Intravenous
newborn
intermittent
infusion: 1.5 mg/kg
every 6 hours
Pediatrics:
90-180 mg/ma
orally every
6-12 hr
Special
considerations:
Dose interruption
for severe
anemia or
granulocytopenia
Most frequent: Co-administration Category: C
Bone marrow with
suppression ganciclovir, Transplacental
(anemia and alpha-interferon, passage: yes
granulocytopenia) dapsone,
flucytosine, or Animal safety: high
Nausea, myalgias, vincristine can doses during
headaches, and increase late gestation
insomnia are hematologic associated with
common and toxicity transplacental
diminish over carcinogenicity
time Phenytoin and in mice
fluconazole can
Less frequent: effect ZDV Human safety:
Long-term levels extensive
administration experience;
has been reversible
associated with anemia in the
peripheral newborn;
myopathy long-term
safety is being
studied Marked elevations
in liver function
tests,
hepatomegaly,
and lactic
acidosis
secondary to
steatosis has
been reported
Follow-up of
children
exposed in
utero is
recommended
zidovudine therapy for the prevention of mother-
to-child HIV-1 transmission. 17 When ZDV, 300 mg
twice daily, was given from 36 weeks of gestation
until the onset of labor and then increased to 300
mg orally every three hours in labor, the transmis-
sion rate was decreased by 51%;. the Kaplan-Meier
estimates of transmission risk were 9.2% in the pla-
cebo group and 18.6% in the placebo group, P
0.008. These findings are consistent with observa-
tional studies in the United States ls,16 and provide
substantial scientific support for using shorter
courses of zidovudine when the complete 076 regi-
men cannot be given.
Results of all three clinical trials are consistent
with the mounting epidemiologic evidence sup-
porting the use of ZDV regimens to prevent
mother-to-child HIV-1 transmission:
TABLE 2. Zidovudine regimen studied in
ACTG O76
Antepartum Intrapartum Newborn
dose dose dose
I00 mg orally 5 2 mg/kg loading 2 mg/kg orally every
times a day, dose, followed hours, initiated
initiated between by continuous within 8-12 hours
14 and 34 weeks infusion of of birth and
of gestation and mg/kg/hr continued for 6
continued until weeks
labor
Nationwide, the number of cases of pediatric
AIDS reported to the CDC declined 47% be-
tween 1992 and t996.18
In North Carolina, mother-to-child transmission
rates have decreased from 21% in 1993 to 6% in
1996 following the use of ZDV. 19
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In New York City, in a cohort of 898 children
followed between July of 1994 and June of 1996,
the transmission rate was 13% in those mother-
infant pairs who received any ZDV, compared
with 26% in mother-infant pairs who received no
ZDV.z
In New York State, an observational study of 943
HIV-exposed infants born after August 1995
found a transmission rate of 6.3% among infants
exposed to the full 076 regimen, an 11.5% trans-
mission rate among infants expensed to ZDV
starting either in labor or in the immediate neo-
natal period, and a 26.5% transmission rate
among infants who received no ZDV prophy-
laxis, zl This is the first report that supports the
efficacy of intrapartum/newborn regimens and
even newborn regimens alone if initiated within
48 hours of birth.
ZDV MECHANISM OF ACTION
AS CHEMOPROPHYLAXIS
At the time of the interim ACTG 076 study analy-
sis, the mechanism by which ZDV reduced the risk
of transmission was unknown. 11 It is now known,
through analysis of viral loads in maternal plasma
samples from entry and delivery, that ZDV appears
to act primarily by a mechanism other than the
reduction of maternal viral burden. Neither the
change in maternal plasma viral load from entry to
delivery nor a critical level at delivery fully ac-
counts for the substantially reduced transmission
rate observed in the ZDV treated group. The pos-
sibility of a significant prophylactic effect in utero
and/or intrapartum (both during and after expo-
sure) has been raised.
Side Effects
Drug Toxicities in Adult Trials
Early studies utilizing 1200 mg/d reported signifi-
cant patient problems with drug-associated toxici-
ties. Later studies demonstrated the efficacy of
500-600 mg/d with significantly reduced toxicity.
The major side effects include anemia and/or
granulocytopenia, headache, fatigue, malaise, nau-
sea, and other gastrointestinal discomforts. Long-
term ZDV therapy has been associated with myop-
athy and rare cases of hepatic steatosis and lactic
acidosis.
Drug Toxicities in Perinatal Transmission Trials
There remains ongoing concerns about the safety
of the 076 regimen, both for the mother and for the
infant. Specific questions have been raised regard-
ing adverse effects of this regimen on the long-
term health of uninfected infants and on maternal
disease progression.
The only infant toxicity associated with the
ACTG 076 regimen has been a mild, reversible
anemia whose nadir has been at 6 weeks of age
with resolution by 12 weeks of age. Infant anemia
was not associated with the duration of maternal
zidovudine treatment. Among uninfected infants
in the ACTG 076 study, there were no differences
between the zidovudine-exposed infants and the
placebo infants in growth patterns, immunologic
parameters (lymphocyte subsets), or the occur-
rence of childhood neoplasias,zz The Antiretroviral
Pregnancy Registry, a collaborative prospective
registry supported by pharmaceutical manufactur-
ers, has not found an association between ZDV
exposure and congenital anomalies among the
cases that have been reported to date.e3
There is no standard battery of safety tests in
animals that are required before a drug is approved
by the FDA for use in humans. Although animal
testing is frequently performed to assess pregnancy
safety, animal data may be difficult to interpret and
may not accurately predict risks to human preg-
nancy. Safety concerns about the use of ZDV in
pregnancy have included concerns about poten-
tial transplacental carcinogenicity. Theoretically,
nucleoside analogs such as ZDV can interfere with
DNA synthesis and are potential carcinogens. In
one rodent model, high doses of zidovudine given
during pregnancy were not associated with adverse
outcomes in offspring, including the development
of tumors,z4 In another model, extremely high
doses of zidovudine administered during preg-
nancy were associated with an increased risk of
tumors in offspring,zs An NIH panel comprised of
clinicians, scientists, and patient advocates re-
viewed all available animal data and unanimously
concluded that the benefits of zidovudine in reduc-
ing perinatal HIV far outweighed the potential
risks. Other recommendations of this panel in-
cluded the need to inform women of these data, to
conduct long-term follow-up on all children ex-
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posed in-utero to ZDV, and to conduct more clini-
cal and basic research on the topic.
In ACTG 076, at 6 months postpartum, there
were no differences in clinical, immunologic, or vi-
rologic disease progression between those women
who received the 076 ZDV regimen and those who
received placebo.2
ZDV Resistance
Monotherapy with antiretroviral agents has been
associated with drug resistance. Drug resistance is
more likely to emerge with increasing duration of
therapy and with advancing immunosuppression.
In the ACTG 076 study, maternal therapy was not
associated with the development of high level zid-
ovudine resistance,z6
ZDV is available in a variety of different formula-
tions (Table 1). Based on average wholesale prices,
the unit cost of the 100-mg capsule is $1.59, the
unit cost of the 300-mg tablet is $4.78, and the unit
cost of a 200-mg bottle for intravenous injection is
$17.30. Cost-effectiveness analyses have estimated
that the ZDV drug cost per treated case following
the ACTG 076 regimen is $895.z7
SUMMARY
Zidovudine was the first agent approved for treat-
ment of HIV disease, and since its widespread
availability in 1987, the pharmacokinetic disposi-
tion and clinical effects of ZDV have been exten-
sively evaluated. In addition to its utility as a com-
ponent of a multidrug combination regimen for the
treatment of adult and pediatric HIV-1 infection, it
is the only agent approved by the FDA for the
prevention of mother-to-child HIV-1 transmission.
The effectiveness of ZDV for the prevention of
mother-to-child HIV-1 transmission has been dem-
onstrated in several studies. The optimal time dur-
ing gestation to initiate ZDV therapy and the rela-
tive importance of the intrapartum and newborn
components is the focus of both current interven-
tional and observational studies. Until more infor-
mation is available from these trials, the combined
maternal/newborn ZDV regimen studied in ACTG
076 remains the recommended treatment regimen
of choice in the United States.
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